Gamida Cell Ltd. (GMDA)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gamida Cell Ltd. (“Gamida” or the “Company”) (NASDAQ: GMDA). The investigation concerns whether Gamida and certain of its officers and/or directors have violated federal securities laws.
On November 11, 2021, Gamida issued a press release providing an update on the Company’s Pre-Biologics License Application (“BLA”) meeting with the U.S. Food and Drug Administration for omidubicel, the Company’s proposed blood cancer treatment. Specifically, Gamida disclosed that “[t]he FDA requested that Gamida Cell provide revised analysis of the manufacturing data generated at Gamida Cell’s wholly-owned commercial manufacturing facility to demonstrate the comparability to the omidubicel that was produced at the clinical manufacturing sites for the Phase 3 study”, a development that the Company acknowledged would bring a “delay in timing to bring omidubicel to patients after a potential FDA approval[.]” On this news, Gamida’s stock price fell sharply during intraday trading on November 11, 2021.
If you are aware of any facts relating to this investigation, or purchased Gamida shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.